FACDX
Price
$60.99
Change
-$1.08 (-1.74%)
Updated
Jul 31 closing price
Net Assets
3.12B
SHSAX
Price
$61.31
Change
-$0.68 (-1.10%)
Updated
Jul 31 closing price
Net Assets
6.09B
Interact to see
Advertisement

FACDX vs SHSAX

FACDX vs SHSAX Comparison Chart in %
View a ticker or compare two or three
VS
FACDX vs. SHSAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FACDX is a StrongBuy and SHSAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
SHSAX has more cash in the bank: 6.09B vs. FACDX (3.12B). SHSAX pays higher dividends than FACDX: SHSAX (0.27) vs FACDX (0.00). FACDX was incepted earlier than SHSAX: FACDX (30 years) vs SHSAX (27 years). SHSAX (1.09) is less costly to investors than FACDX (0.93). FACDX is a more actively managed with annual turnover of: 52.00 vs. SHSAX (43.00). FACDX initial investment is less costly to investors than SHSAX (5%) vs SHSAX (5%). FACDX has a lower initial minimum investment than SHSAX: FACDX (0) vs SHSAX (1000). FACDX annual gain was more profitable for investors over the last year : 14.64 vs. SHSAX (8.10). FACDX return over 5 years is better than : -12.35 vs. SHSAX (-20.78).
FACDXSHSAXFACDX / SHSAX
Total Expense Ratio0.931.0985%
Annual Report Gross Expense Ratio0.931.0985%
Fund Existence30 years27 years-
Gain YTD8.581-5.283-162%
Front Load6%5%110%
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets3.12B6.09B51%
Annual Yield % from dividends0.000.27-
Returns for 1 year14.648.10181%
Returns for 3 years2.83-4.99-57%
Returns for 5 years-12.35-20.7859%
Returns for 10 years60.0425.96231%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPRA18.900.23
+1.23%
Opera Limited
DRDBU11.14N/A
N/A
Roman DBDR Acquisition Corp. II
AGX570.43-9.44
-1.63%
Argan
SORA1.65-0.04
-2.37%
AsiaStrategy
CATX2.91-0.08
-2.68%
Perspective Therapeutics